Unveiling the Role of Biomarkers in Cardiovascular Risk Assessment and Prognosis.

ABSTRACT

Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, necessitating innovative approaches for accurate risk assessment and prognosis. This review explores the evolving role of biomarkers in advancing cardiovascular risk evaluation and prognostication. Utilizing cardiac biomarkers that represent diverse pathophysiological pathways has the potential to enhance risk stratification for CVD. We delve into the intricate molecular signatures indicative of cardiovascular health, focusing on established biomarkers such as troponins, natriuretic peptides, and lipid profiles while also examining emerging candidates like microRNAs and inflammatory markers. This review provides a holistic perspective on the current landscape of cardiovascular biomarkers, offering insights into their applications in risk assessment and prognosis. In evaluating the risk and prognosis of heart failure (HF), the measurement of natriuretic peptides (B-type natriuretic peptide [BNP] or N-terminal pro-B-type natriuretic peptide [NT-proBNP]) or markers of myocardial injury (cardiac troponin I [TnI] or T [TnT]) has demonstrated utility. By elucidating the synergistic interplay between traditional markers and cutting-edge technologies, this work aims to guide future research endeavors and clinical practices, ultimately contributing to more effective strategies for risk assessment and prognosis of cardiovascular disease.